公开(公告)号：US20170143668A1

公开(公告)日：2017-05-25

申请号：US15415883

申请日：2017-01-26

Applicant: Macau University of Science and Technology

Inventor： Wen-zhe MA ,  Sen-ling FENG ,  Xiao-jun YAO ,  Zhong-wen YUAN ,  Liang LIU ,  Ying XIE

IPC: A61K31/366 ,  A61K31/704 ,  A61K31/337

CPC classification number: A61K31/366 ,  A61K31/337 ,  A61K31/352 ,  A61K31/704 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention discloses a pharmaceutical composition of treating multidrug resistance cancer, comprising a citrus methoxyflavone and a chemotherapeutic drug, in which the citrus methoxyflavone is nobiletin. A method of treating multidrug resistance cancer comprising administrating citrus methoxyflavone and a chemotherapeutic drug is also disclosed.

公开(公告)号：US20170027901A1

公开(公告)日：2017-02-02

申请号：US14848358

申请日：2015-09-09

Applicant: Macau University of Science and Technology

Inventor： Wen-zhe MA ,  Sen-ling FENG ,  Xiao-jun YAO ,  Zhong-wen YUAN ,  Liang LIU ,  Ying XIE

IPC: A61K31/353 ,  A61K31/704 ,  A61K31/337

CPC classification number: A61K31/366 ,  A61K31/337 ,  A61K31/352 ,  A61K31/704 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention discloses a pharmaceutical composition of treating multidrug resistance cancer, comprising a citrus methoxyflavone and a chemotherapeutic drug, in which the citrus methoxyflavone is nobiletin. A method of treating multidrug resistance cancer comprising administrating citrus methoxyflavone and a chemotherapeutic drug is also disclosed.

Abstract translation: 本发明公开了一种治疗多药耐药性的药物组合物，其包含柑橘类甲氧基黄酮和化学治疗药物，其中柑橘类甲氧基黄酮是诺贝利林。 还公开了一种治疗多药耐药性的方法，其包括施用柑橘甲氧基黄酮和化疗药物。

公开(公告)号：US20170027900A1

公开(公告)日：2017-02-02

申请号：US14848360

申请日：2015-09-09

Applicant: Macau University of Science and Technology

Inventor： Wen-zhe MA ,  Sen-ling FENG ,  Xiao-jun YAO ,  Zhong-wen YUAN ,  Liang LIU ,  Ying XIE

IPC: A61K31/352 ,  A61K31/704 ,  A61K31/337

CPC classification number: A61K31/352 ,  A61K31/337 ,  A61K31/704 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention discloses a pharmaceutical composition of treating multidrug resistance cancer, comprising a citrus methoxyflavone and a chemotherapeutic drug, in which the citrus methoxyflavone is tangeretin. A method of treating multidrug resistance cancer comprising administrating citrus methoxyflavone and a chemotherapeutic drug is also disclosed.

Abstract translation: 本发明公开了一种治疗多药耐药性的药物组合物，其包含柑橘类甲氧基黄酮和化学治疗药物，其中柑橘类甲氧基黄酮为甜菜碱。 还公开了一种治疗多药耐药性的方法，其包括施用柑橘甲氧基黄酮和化疗药物。

公开(公告)号：US20160106730A1

公开(公告)日：2016-04-21

申请号：US14985414

申请日：2015-12-31

Applicant: Macau University of Science and Technology

Inventor： Kam Wai WONG ,  Yuen Kwan LAW ,  Liang LIU ,  Jingrong WANG

IPC: A61K31/4725

CPC classification number: A61K31/4745 ,  A61K31/4725 ,  A61K31/4748

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.

公开(公告)号：US20150297582A1

公开(公告)日：2015-10-22

申请号：US14296477

申请日：2014-06-05

Applicant: Macau University of Science and Technology

Inventor： Elaine Lai-Han LEUNG ,  Liang LIU ,  Xing-Xing FAN

IPC: A61K31/4741 ,  G01N33/50 ,  C12Q1/68 ,  A61K33/40

CPC classification number: A61K31/4741 ,  A61K33/40 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/156 ,  G01N33/5011 ,  G01N2333/90209 ,  G01N2333/91205 ,  A61K2300/00

Abstract: The present invention relates to methods for novel drug discovery, treatment and selective targeting for Gefitinib-resistant non-small-cell lung cancer (NSCLC) harboring an additional mutation, in particular, to the discovery of a drug candidate or agent identified by the presently claimed method for use in treating and selective targeting Gefitinib-resistant NSCLC harboring T790M mutation.

Abstract translation: 本发明涉及具有另外突变的吉非替尼耐药性非小细胞肺癌（NSCLC）的新药物发现，治疗和选择性靶向的方法，特别涉及目前鉴定的候选药物或药物的发现 所述方法用于治疗和选择性靶向具有T790M突变的吉非替尼耐药性NSCLC。

公开(公告)号：US20150190392A1

公开(公告)日：2015-07-09

申请号：US14562781

申请日：2014-12-08

Applicant: Macau University of Science and Technology

Inventor： Kam Wai WONG ,  Yuen Kwan LAW ,  Liang LIU ,  Jingrong WANG

IPC: A61K31/4745 ,  A61K31/4725

CPC classification number: A61K31/4745 ,  A61K31/4725 ,  A61K31/4748

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.

Abstract translation: 本发明公开了一种治疗癌症的方法，该方法包括给予有效量的生物碱，其中生物碱为留丝氨酸，依沙星碱，屈酸，去甲肾上腺素，栀子或沙利度胺，并从中药中分离出来。 还公开了使用生物碱治疗神经变性疾病。

公开(公告)号：US20150164885A1

公开(公告)日：2015-06-18

申请号：US14562780

申请日：2014-12-08

Applicant: Macau University of Science and Technology

Inventor： Yuen Kwan LAW ,  Kam Wai WONG ,  Liang LIU

IPC: A61K31/4725 ,  A61K36/185

CPC classification number: A61K31/4725 ,  A61K36/62

Abstract: The present invention discloses a method of treating neurodegenerative disorder comprising administering an effective amount of an alkaloid which is a bisbenzylisoquinline alkaloid isolated from the traditional Chinese medicinal herb Nelumbo nucifera. The pharmaceutical composition thereof for treating Huntington's disease is also disclosed.

Abstract translation: 本发明公开了一种治疗神经变性疾病的方法，包括给予有效量的生物碱，所述生物碱是从中草药Nelumbo Nucumera分离的双苄基异喹啉生物碱。 还公开了其用于治疗亨廷顿病的药物组合物。

公开(公告)号：US20140135278A1

公开(公告)日：2014-05-15

申请号：US14040738

申请日：2013-09-30

Applicant: Macau University of Science and Technology

Inventor： Liang LIU ,  Liping BAI ,  Hang DONG ,  Kam Wai WONG ,  Zhihong JIANG ,  Hua ZHOU

IPC: C07J17/00

CPC classification number: C07J17/005

Abstract: The present invention relates to a novel compound derived from ginsenoside Rh2, the preparation methods and the use thereof in treating cancers.

Abstract translation: 本发明涉及一种衍生自人参皂苷Rh2的新型化合物，其制备方法及其在治疗癌症中的应用。